OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Thoracic Oncology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response	350
Board of Directors	220
PP01.172 It's Never Too Late To Quit	209
PP01.112 Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study	205
PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis	164
PP01.26 Proprietary vs Open-Source Radiomic Platform for Lung Cancer Diagnosis	142
In This Issue	140
Why and When Do We Invasively Restage After Neoadjuvant Chemoimmunotherapy?	135
Comment on “MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC”	134
EP.02A.02 The Stroma Cell Function in the Border Region Between Lung Cancer and Normal Lung	131
EP.09.05 Efficacy and Prognostic Factors of Radiotherapy in Brain Metastases From Non-Small Cell Lung Cancer Patients:A Retrospective Study	125
OA01.04 Investigating the Association Between Procedure Duration of Coronary Angiography and Intervention and Postoperative Cancer Risk	122
P1.11.03 Long-Term Efficacy of Immune Checkpoint Inhibitors in Pulmonary Cancer With Rhabdoid Features: A Single-Center Retrospective Analysis	121
P2.15.17 Preliminary Results on Feasibility of Virtual Delivery of Exercise Therapy for Mitigation of Lung Cancer Decline	118
P2.15.15 Impact of Palliative Care in Patients With Non-Small Cell Lung Cancer and Brain Metastases: A Retrospective Quality Analysis	112
P1.11.04 Prediction of Overall Survival in Lung Cancer Patients With Different Organ Metastases: A SEER Population-Based Cohort Study	108
EP.02.05 Three-Dimensional Visualization of Spreading Tumor Cell Through Air Spaces (STAS) Using High Resolution Phase-Contrast Imaging Method	105
P3.16.09 A Study of Testing Knowledge Regarding Lung Cancer Screening Among General Population and Caregivers	104
EP.13.08 Early Hospitalization During Chemoradiation for Limited-Stage Small Cell Lung Cancer Is Associated With Inferior Survival	102
EP.12.06 Brilliant First Analysis: A Real-World Study of Characteristics and Safety About Brigatinib as First-Line for Chinese Patients With ALK+ NSCLC	101
P3.12.09 Efficacy of Tepotinib Against Non-Adenocarcinoma MET Exon 14 Skipping NSCLC: A Subanalysis of the REAL-MET Study	100
EP.04.42 Alunghive: Autonomous Registry and Analytics System to Transform Clinical Workflow and Enable Multicenter Lung Cancer Screening Research	96
EP.16.07 Addressing Unmet Needs of the Lung Cancer Community: The Journey to Find and Implement Mind Over Matter	95
P2.02.33 Radiotherapy Induces Ferroptosis and Activates STING Pathway to Reverse Immunotherapy Resistance in LKB1-Mutant Lung Cancer	89
EP.13.20 Stereotactic Body Radiotherapy for Limited-Stage Small Cell Lung Cancer: Outcomes From a Single-Institution Retrospective Study	89

P3.13.26 Sequencing of Stereotactic Body Radiation Therapy and Chemotherapy in Stage I Small Cell Lung Cancer: Practice Patterns and Outcomes	89
P3.12.43 A Phase II Study of Sunvozertinib Combined With Anlotinib in NSCLC Patients Harboring EGFR Ex20Ins and Uncommon EGFR Mutations	89
MA06.01 Real-World Outcomes of First-Line Immunotherapy Intensification of Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC)	87
EP.17.29 Real-World Effectiveness of Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Without Oncogenic Driver Alteration	87
OA10.02 Bevacizumab Plus Chemotherapy Versus Chemotherapy in Untreated Non-Squamous NSCLC With Brain Metastases: A Randomized, Phase 3 Study	86
P1.17.27 Assessing Sarcopenia in Lung Cancer: Feasibility and Training Considerations of Using Quantitative Imaging Metrics From CT Scans	84
P2.10.10 Soluble Ceacam5 Resistant ADC for Effective Tumor Targeted Delivery With Clinically Validated Tumor Selective Linker Payload	80
P2.08.44 Adverse Cardiovascular Events Related to Immune Checkpoint Inhibitors in Staging IB-IIIb Non-Small Cell Lung Cancer: A Real-World Study	79
EP.06.78 T Lymphocyte Subpopulations as Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Anti-Pd(L)1 Inhibitors	78
EP.05.03 Analysis of Left Upper Pulmonary Arterial Bronchial Concomitant Consistency Based on Three-Dimensional Reconstruction	73
EP.15.07 Living With Lung Cancer-A Qualitative Exploration of Its Psychosocial Impact	72
P3.01.17 Age-Sex Disparities in Global Burden and Trend of Lung Cancer and Its Attributable Risk Factors in the United Kingdom From 1990-2021	72
EP.12.38 Firmonertinib(160Mg) Combined With Chemotherapy as First-Line Treatment for Advanced NSCLC Patients With EGFR Mutations and Cns Metastases	72
EP.11.14 Impact of Bone Metastases on the Efficacy of First-Line Immunotherapy in Advanced NSCLC: An Analysis From a Prospective Real-World Study	72
PT2.16.04 Advancing Lung Cancer Advocacy in Low- and Middle-Income Countries	71
P3.13.02 The Effectiveness of Anatomical Versus Non-Anatomical Resection for Treatment of Small Cell Lung Carcinoma	70
P3.12.36 Multicenter Retrospective Study of Selpercatinib Treatment for Advanced or Recurrent RET Fusion-Positive NSCLC in Japan	69
PT1.03.02 Single-Cell Profiling of Tumor Lineage Plasticity and the Immune Microenvironment in Transformed Small Cell Lung Cancer	69
P1.17.63 Docetaxel and Docetaxel Plus Ramucirumab Demonstrate Similar Real-World Overall Survival: A Contemporary Analysis	68
P1.17.17 Financial Distress and Concerns Prior to Cancer-Directed Treatment Among Patients With NSCLC	66
EP.08D.06 Neoadjuvant Chemoimmunotherapy Does Not Increase Postoperative Morbidity of Pneumonectomy in NSCLC Patients: A Multi-Center Psmanalysis	66
EP.01.19 Characteristics of Lung Cancer in Never- and Light-Smokers: A Retrospective Study From Greece	66
P1.08C.05 The Clinicopathological and Prognostic Significance of Skip-N2 Metastases: A Retrospective Multicenter Study	65
P4.11E.02 Efficacy of Pembrolizumab Plus Pemetrexed in Older Patients with Non-squamous NSCLC According to PD-L1 Status from the CJLSG1901 Study	64
EP.06D.02 Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib	63
P2.17B.02 Healthcare Providers' Perceptions of Barriers and Enablers to Adopting New Surveillance Protocols	62
EP.07F.06 Prospective Study of Breath Hold During SBRT Treatment of the Lung: Analysis Reliability of Surface Guidance Alone for Breath Hold	61
EP.12A.10 Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients	61
P2.17B.03 Improving Lung Cancer Screening Utilization and Efficiency Through a Patient-Centered Pathway with Virtual Visits	60
EP.08F.18 Survival and Incidence Trends of Non-Small Cell Lung Cancer in Elderly Patients (>75 Years): Insights from SEER Database	59
EP.11A.16 Infusion Timing of ICI Monotherapy in Patients with Advanced NSCLC: A Single Institution-Retrospective Study	56
P1.01C.04 Key Stakeholder Priorities on Embedding Smoking Cessation Into Lung Cancer Screening: National Australian Consensus Workshop	56
MA18.09 Comparing Efficient Lung Cancer Screening Strategies for Black and White Americans	56
EP.14C.08 Challenges in Diagnosis and Management of Epithelioid Inflammatory Myofibroblastic Sarcoma - Case Report	55
P4.11E.13 Real-World Treatment Patterns, Healthcare Cost and Resource Utilization in First-Line Treatment of Metastatic NSCLC in the US	55
EP.04A.16 Cost-Effectiveness of Adaptive Schedules for Lung Cancer Screening: A Modeling Study	55
P2.14A.10 Real-World Evidence of Ipilimumab Plus Nivolumab Combination Therapy in Patients with Malignant Pleural Mesothelioma	55
P3.08E.01 Perioperative Chemoimmunotherapy Rescue Cold HLA-Deficient Tumors Inducing Strong Immune Responses and Long-Term Survival	54
P2.11A.26 Prognostic Utility of Peripheral Myeloid Cells for Clinical Outcomes in Patients with NSCLC Treated with Cemiplimab	54
EP.07A.08 Modified Periareolar Incision for Uniportal Segmentectomy	52
EP.12A.08 Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A Real-World Study	51
EP.16A.01 Patient Experiences of Biomarker Testing: Insights from a Global Patient Experience Survey	51
EP.15B.04 High-Fiber Intake Predicts Overall Survival in Lung Cancer Patients - Real-World Analyses	51
P2.04A.07 Improving IPN Management Through CAD and Virtual Nodule Clinics: A Prospective, Observational Multicenter Study (PINPOINT)	51
EP.07E.02 Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer	49
P1.01A.01 The INHERIT Study - Investigating Hereditary Risk in Thoracic Cancers (NCT05587439)	49
P2.11C.01 With Eyes on the Future: Prospective Evaluation of Immune-Related Adverse Events in Patients with Lung Cancer	49
EP.13D.07 Impact of Antiemetic Steroid Use on Survival in Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors and Chemotherapy Combination	49
P3.03I.08 Efficacy of Novel Third-Generation Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations- Anin Vitrostudy	48
EP.03F.05 A Dose-Effect Relationship of a Novel Bronchoscopy Guided Endobronchial Radiofrequency Ablation for Peripheral Lung Tumors	48

MA11.13 Peripheral T-Cell Receptor Repertoire Differentiates a Typical Progression in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy	47
MA04.05 An Evolution and Expanding Engagement to Excel in Lung Cancer Screening	47
OA04.06 The Global Landscape of Lung Squamous Cell Carcinoma, Lung Adenocarcinoma, Small Cell Lung Cancer Incidence in 2020	47
EP.11A.05 Use of Immune Checkpoint Inhibitors in Advanced NSCLC Cases with Very Poor ECOG-PS: A Real World Experience	47
MA07.09 Genome-Wide CRISPR Screen Identifies SFRP2 as a Novel Stromal Target to Enhance Abscopal Effect of Radioimmunotherapy	47
EP01.04-001 A Programmatic Approach to Improve Efficiency in Lung Cancer Screening	46
A Response to the Letter to the Editor: “Comparable or Indeterminate? A Critical Appraisal of Efficacy Claims in the MARIPOSA Exploratory Analysis”	46
OA08.06 Implementation of a Nurse-led Geriatric Oncology Assessment Model in the Lung Cancer Care Pathway	46
Lung Cancer in the Philippines	46
Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib	45
MA04.09 The Incidence and Predictors of Unsuspected Brain Metastases in Patients with Stage IA NSCLC	45
EP08.02-163 Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer	44
EP07.03-001 Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma	44
Editorial Board	44
EP04.01-012 Sex and Age-Related Guideline-Adherence Disparities in Non-Small-Cell Lung Cancer Treatment Patterns: Real-World Data	43
EP14.05-019 Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-2021	43
EP16.03-018 Molecular Features of Subtypes Classified Based on Predominance and Components in Chinese Patients with Lung Adenocarcinoma	43
EP14.02-006 Subtype-specific Hypersensitivity to Oxidative Phosphorylation Inhibition in Small Cell Lung Cancer	43
EP08.01-021 Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy	43
EP01.07-001 Surveillance with FDG PET/CT after Completion of Therapy for NSCLC: A Status Update on Inclusion in the SUPE_R Trial	43
In Response to Continuation of Lorlatinib Beyond Progressive Disease	42
EP08.01-079 Long Term Use of Immune Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer (NSCLC) and Abnormal Marrow Pathology: A Case Series	42
EP07.01-024 Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma	42
EP08.01-055 Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer	42
European Society of Thoracic Surgeons (ESTS)	41
EP01.01-007 Incorporating cfDNA Detection to CT Scan Assessment in Post-Surgical Lung Cancer Patients	41
P2.20-05 The Impact of Preoperative Immunotherapy On Peri-Operative Outcomes After Thymectomy for Thymic Epithelial Tumors	40
OA15.05 Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC	40
P1.25-13 Enhanced Assessment Of Recurrence Risk Of Stage I NSCLC By Combined Adenocarcinoma Grading System And Serum Proteomic Testing	40
218P Implications of the eighth edition of TNM staging system for thymoma, a single-center retrospective study	39
EP08.02-119 RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer	39
213P Development of an explainable clinical decision support tool for advanced lung cancer patients	38
Table of Contents	38
In This Issue/Research Watch/News in Brief	37
Response to Letter to the Editor From Binghao Zhao et al	37
EP07.02-15 Longitudinal ctDNA Testing in Resected, Early Stage Non-small Cell Lung Cancers	36
EP11.03-004 Identification of Filigree Pattern Increases Diagnostic Accuracy of Micropapillary Pattern on Frozen Section for Lung Adenocarcinoma	36
The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven	36
EP04.01-001 Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience	35
73P Qualitative research to evaluate perceptions around biomarker testing and patient-reported outcomes (PROs) for use in studies of non-small cell lung cancer (NSCLC)	35
50P Patient-reported outcomes in non-small cell lung cancer patients receiving immunotherapy monotherapy: Analysis from enhanced, EHR-facilitated cancer symptom control (E2C2) pragmatic clinical trial	35
PP.04 EGFR Structure-Based Classification and Presence of Commutations in Peruvian Patients With Advanced Lung Cancer	35
Editorial Board	34
OA11.06 Sequencing of ctDNA Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis	34
115P Salvage surgery in patients with locally advanced or metastatic non-small cell lung cancer	34
EP14.03-12 Anastomosing Hemangioma of Mediastinum and Pleura Mimicking Chest Malignancy	34
EP08.02-027 T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC	34
EP08.02-100 Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression	33
P1.25-15 Trends and Disparities in Curative-Intent Treatment for Early-Stage Non-Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT	33
EP01.02-006 Excuse Me? Patient Perceptions of Lung Cancer Screening Results	33
EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study	33
Establishment of Tumor Immune Microenvironment Classification Model to Select Patients Sensitive to Immunotherapy	33
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC	32
EP12.01-44 A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib	32
P1.22-02 Whole Genome Sequencing Analysis of ALK-rearranged Non-small Cell Lung Cancer	32
P2.13-02 Molecular Subtyping of Small Cell Lung Carcinoma: An Attempt at Unravelling Its Biological Heterogeneity	31
P1.21-11 Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%	31
EP12.01-73 Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy	31
EP11.03-31 Quantification of Interstitial Lung Abnormality Using Deep Learning in Cancer Patients Who Underwent Immune Checkpoint Inhibitors	31
P1.16-03 Transbronchial Cryobiopsy Using 1.1 mm-Diameter Cryoprobe for the Diagnosis of Early Stage Lung Cancer	31
63P Inflammatory indexes and treatment response as correlates of pembrolizumab effectiveness in patients with PD-L1≥50%: Data from the real-life practice	30
EP05.01-11 Lung Cancers Diagnosed in a Retrospective Cohort of Lung Nodule Patients in Singapore	30
EP14.03-07 Three Cases of Mediastinal Teratoma Resulting in Thoracic Perforation	30
EP12.01-62 Osteoblastic Bone Reaction in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Treated with Osimertinib	30
EP07.04-10 Early-Stage EGFR Mutated NSCLC: Outcomes After Surgical Resection at a Large Academic Medical Center	30
EP04.04-05 Ten-year CTNB Data Indicate Its Usefulness and Safety, Especially Salvage Situation after Bronchoscopy without Diagnosis	30
EP13.01-10 Mitotic Counts and Phospho-Histone H3 Index in Grading Pulmonary Neuroendocrine Tumors: Assessment of Interobserver Variability and Utility	29
OA12.03 An Analysis of the Rate of Second Primary Lung Cancer from CALGB (Alliance) 140503 Trial of Lobar versus Sub-Lobar Resection for T1aN0 NSCLC	29
P1.05-01 Research on Specific DNA Methylation Regulatory Mechanism Based on Pan-Cancer Analysis	29
MA10.05 Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review	28
EP03.03-06 The Involvement of Tumor Endothelial Cells in the Regulation of PD-L1 and Tregs in the Immune Microenvironment of Early-stage Lung Adenocarcinoma	28
25P Furmonertinib plus icotinib for first-line treatment of EGFR-mutated non-small cell lung cancer	28
EP11.04-01 Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer	28
Board of Directors	28
EP04.06-04 Impact of a Navigational Program on Lung Cancer Screening at a Community Health Center Serving an Urban Diverse Population	27
P1.25-07 Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR	27
EP03.02-03 High-Throughput Screening Reveals Ceritinib as a Sensitizer for Cafs-Induced Osimertinib Resistance in Non-small Cell Lung Cancer	27
WS08.07 Evaluation of a Risk-sharing Agreement for Atezolizumab Treatment in NSCLC Patients: A Strategy to Improve Access in Low Income Countries	27
EP01.01-09 Radiation Exposure in Intraoperative Navigation for Peripheral Small Pulmonary Nodule	27
P2.07-08 Checkpoint Inhibitor Pneumonitis Model for NSCLC based onPreexistingLung Ground Glass Opacities: Development and Validation	27

P2.17-02 EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study	27
EP05.01-04 A Retrospective Study on the Efficacy and Safety of Flexible Bronchoscopy in Elderly Patients with Suspected Primary Lung Cancer	26
P1.26-05 Sublobar Resection is Equivalent to Lobectomy for Stage IA Adenocarcinoma Presenting as Subsolid Nodule	26
Meeting Announcements	26
EP17.04-01 The Impact of the Emergency Presentation of Patients Diagnosed with Lung Cancer on Treatment Outcomes in Wales	26
EP07.04-17 Study on the Regulatory Mechanism of OM-85 BV on the Immune Microenvironment of Clinical Early-stage Lung Adenocarcinoma	26
MA03.06 Respiratory Tract Malignancy-associated Mortality Attributable to Particulate Matter in South Asia from the Global Burden of Disease	26
EP11.03-39 Platinum/Taxane versus Docetaxel +/- Ramucirumab for Metastatic Lung Cancers That Progressed on Platinum Doublets and Anti-PD1/PD-L1	26
P2.07-01 Deep-Learning Based Prediction of c-MET Status from Digitized H&E-Stained Non-Small Cell Lung Cancer Tissue Samples	26
In This Issue/Research Watch/News in Brief	26
Meeting Announcements	26
P1.26-06 Harmonized Maximum Standardized Uptake Value as an Indicator for Sublobar Resection: A Multicenter Retrospective Study	26
P1.17.49 Real-World Outcomes With IO and Chemo-IO Demonstrate Unmet Need for 1L KRAS G12C-Mutant Advanced NSCLC in the US	26
P2.11A.23 Fecal Microbiota Transplantation Plus Rechallenging Immunotherapy in Patients with Advanced Non Small Cell Lung Cancer: An Exploratory Study	25
253P: Surgical vs non-surgical management of non-small cell lung cancer with brain metastases	25
27P: Impact of platinum-based chemotherapy (CT) on acquired resistance (AR) to first-line immunecheckpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC): Individual patient data metanalysis	25
EP01.06-002 Impact of Immediate AI Enabled Patient Triage to Chest CT on the Lung Cancer Pathway: LungIMPACT	25
P4.11D.05 EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy	25
PP01.12: Is There a Role for Minimally Invasive Thoracoscopic Lobectomy in Patients with Unexpected N+ Non-Small Cell Lung Cancer?	25
348P: Pulsed high-dose fractionated radiotherapy combined with enhanced immunotherapy in the treatment of driver gene-negative advanced non-small cell lung cancer: A clinical study	25
32P: The impact of renal dysfunction and pemetrexed administration dose in KEYNOTE189 on prognosis	25
PP01.25 Exploring the Impact of Socioeconomic and Geographic Factors on Immunotherapy Discontinuation and Success in Northern Ontario: A Retrospective, Single-Center Cohort Study	25
EP05.01-023 Feasibility of Functional Lung Avoidance using Ga-68 4D Ventilation Perfusion PET/CT: The HI-FIVE Trial	25
Screening Lung Cancer in Population-Based Real-World Programs: Searching for Efficiency Indicators	25
422P: Acute pneumonitis in patients receiving thoracic radiotherapy and pre-treated with immune checkpoint inhibitors	25
312P: Correlation between immune-related adverse events (irAEs) and survival outcomes in extensive-stage small cell lung cancer (ES-SCLC) patients (pts) treated with chemoimmunotherapy (CT-IO)	25
60P: The FIN-EGFR study: A retrospective observational study to investigate the treatment landscape and outcomes of early and advanced stage patients with EGFR mutated non-small cell lung cancer (NSCL	24
Predicted Effect of Incidental Pulmonary Nodule Findings on NSCLC Mortality	24
Editorial Commentary: Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC	24
390P: Evaluate the effects of VMAT and IMRT treatment techniques on critical organs with different treatment planning algorithms	24
EP08.01-093 ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer	24
Corrigendum to ‘Surveillance With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of Patients With Stage I-to-III Lung Cancer After Completion of Curative treatment (SU	24
181P: Evaluating probe-based confocal laser endomicroscopy for lung nodule diagnosis: A comprehensive systematic review and meta-analysis	24
OA16.03 Telisotuzumab Vedotin in Asian Patients with C-Met Protein-Overexpressing Non-Squamous EGFR WT NSCLC: Results from LUMINOSITY	24
Tobacco News Update - From the IASLC Tobacco Control Committee	24
273P: Effect of lung cancer screening, smoking cessation and cessation smartphone application to health-related quality of life	23
Can Immunotherapy Be Omitted in KRAS G12C-Mutant Lung Cancer by 2025?	23
Making PACIFIC Flowers Bloom: Results From the AYAME Study	23
PP01.24: Real-World Safety and Outcomes of Tarlatamab in Extensive-Stage Small Cell Lung Cancer	23
PP01.16: Financial Distress and Concerns Prior to Cancer-Directed Treatment Among Patients With NSCLC	23
Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?	23
Lung Cancer in Romania	23
Rethinking Biomarkers for Combination Chemoimmunotherapy	23
PP01.25: Safety and Preliminary Efficacy of Zanidatamab in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer (NSCLC): Subgroup Analysis from a Phase 1 Study	23
MA01.04 AFT-46: CHIO3: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer	23
PP01.26: Real-World Time Toxicity of Tarlatamab in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)	23
Translational Analysis of NSD3 Gene Amplification in Lung Squamous Cell Carcinoma: Clinical and Prognostic Insights From Histopathologic Analysis of Patient Samples	23
OA01.06 A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer	22
MA17.05 Real World Outcomes of Immunotherapy (IO) for Pleural MESOthelioma in Australia - RIOMeso	22
Iruplinalkib (WX-0593), the Seventh ALK Tyrosine Kinase Inhibitor Approved in People's Republic of China With More to Come	22
EP.04A.01 Lung Cancer Nurse Consultant-Led Pulmonary Nodule Assessment and Surveillance Clinic: Multidisciplinary Team Evaluation	22
Current and Future Treatment Options in the Management of Stage III NSCLC	22
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion	22
EP.12A.22 Aumolertinib with Chemotherapy as First-Line Treatment in Patients with EGFR-Mutated Advanced NSCLC: A Real-World Study	22
The 2024 International Association for the Study of Lung Cancer Global Survey on Biomarker Testing	21
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer	21
P2.01-05 The Safety and Efficacy of Induction Chemoimmunotherapy Followed by Radiotherapy and Consolidation Immunotherapy in Locally Advanced NSCLC	21
Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis	20
Impact of Genomic Subtype on Intracranial Outcomes in Treatment-naive EGFR mutant NSCLC with Osimertinib (IGnITE)	20
OA10.03 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up	20
Selective Depletion of CCR8+Treg Cells Enhances the Antitumor Immunity of Cytotoxic T Cells in Lung Cancer by Dendritic Cells	20
PPD01.03: Real World Data On Lung Cancer Detection In A High-Risk Population In A Colombian Insurance Company	20
Bidirectional Association Between Cardiovascular Disease and Lung Cancer in a Prospective Cohort Study	20
357P: Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC)	20
PP01.21: Evaluating the Accuracy & Reproducibility of ChatGPT Models in Answering Patient’s Lung Cancer Queries	20
Serum microRNAs are Associated with Treatment Response and Disease Progression in Limited Stage Small Cell Lung Cancer	20
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial	20
EP.12A.39 MET Point Mutations as the Mechanism of Resistance to EGFR-TKI Therapy: A Case Report of MET H1094Y-Mediated Resistance to Osimertinib Overcome by Capmatinib and a Systematic Review.	20
Table of Contents	20
FBXO11 Mediates PARP Inhibitor Resistance in Small-Cell Lung Cancer	20
102P: Molecular characteristics and spatially resolved proteomic immune clusters reveal responsiveness of large cell neuroendocrine carcinomas of the lung (LCNEC) towards the Checkmate-9LA treatment p	19
248TiP: Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemoimmunotherapy in resectable epithelioid and biphasic pleural mesothelioma (CHIMERA	19
Board of Directors	19
EP08.02-116 Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors	19
303P: Identifying novel prognostic markers in small cell lung cancer through comprehensive in-silico analysis	19
310P: Final overall survival (OS) of surufatinib plus PD-1/PD-L1 antibodies as maintenance therapy following first line (1L) platinum-based chemotherapy (Chemo) plus PD-1/PD-L1 antibodies in patients	19
240P: Real-world toxicity data for the use of ipilimumab plus nivolumab in malignant mesothelioma across 11 UK centres	19
205P: EGFR-TKI combined with chemotherapy versus EGFR-TKI alone for locally advanced EGFR-mutant NSCLC: A real-world study	19
215P: Safety and necessity of mediastinal lymph nodes dissection omission following nodal clearance with neoadjuvant immunochemotherapy in cN0/N1 non-small cell lung cancer	19
137MO: Impact of cardiac substructure dose on cardiotoxicity and overall survival (OS) in early-stage non-small cell lung cancer (ES-NSCLC) patients receiving stereotactic ablative body radiotherapy (	19
381P: Empowering global oncology: DBS-TARGETenables high-sensitivity mutation detection anywhere	19
PP01.25 Burden of Chemotherapy-induced Myelosuppression on Patients with Extensive-stage Small Cell Lung Cancer (ES-SCLC) from the Perspective of Patients and Caregivers	18
235P: A stage III, non-small cell lung cancer (NSCLC) multidisciplinary meeting (MDT) to increase access to concurrent chemo-radiation in a Northern UK cancer centre	18
PP01.76 Optimizing Biomarker Models for Biologically-Heterogeneous Cancers: A Nested Model Approach for Lung Cancer	18
144P: Perioperative immunotherapy treatment in resectable non-small cell lung cancer with KRAS mutation: A real-world study (Peri-R-01)	18
Selpercatinib Controls Central Nervous System Disease in Patients With NSCLC With RET Fusion	18
212P: Recurrence in patients with non-small cell lung cancer achieving pathological complete response after neoadjuvant treatment	18
EP08.02-003 Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis	18
398P: The roles of ‘Quinacrine’ (QC) in cell migration and angiogenesis are pivotal to the metastatic spread of human lung cancer cells cultured in vitro and xenograft mouse models	18
PP01.118 First-line Nivolumab (N) + Ipilimumab (I) + Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update	18
PP01.98 Association between pathological upstaging and overall survival among patients who received anatomic sublobar resection versus lobectomy for lung cancer	18
EP12.01-71 Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure	18
150P: Pathologic complete response (pCR) and major pathologic response (MPR) as surrogate endpoints of survival in immunotherapy trials for early-stage NSCLC	18
EP.14.14 Cyclophosphamide/Pegylated Liposomal Doxorubicin/Cisplatin as First-Line Treatment for Patients With Advanced Thymic Epithelial Tumors	17
P3.16.06 The Saving Lungs Behind the Chair Model Is Increasing Lung Cancer Awareness in US Black Communities	17